节点文献

美托洛尔治疗心衰时脑利钠肽的动态变化

Studies on the dynamic changes in brain natriuretic peptide of patients with heart failure treated with metoprolol (a report of 65 cases)

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 张辉弓向荣刘敏张培丽崔超巍闫春玲

【Author】 Zhang Hui, Gong Xiangrong, Liu Min, et al. Department of Cardiology, The Forth Affiliated Hospital of Zhengzhou University, Zhengzhou 450044, China

【机构】 郑州大学第四附属医院心内科郑州大学第四附属医院心内科

【摘要】 目的观察慢性充血性心力衰竭(CHF)患者接受选择性β受体阻滞剂美托洛尔治疗后血浆脑利钠肽(BNP)水平的动态变化,探讨美托洛尔在心衰预后中的临床意义。方法65例CHF患者随机分为美托洛尔组(34例)和对照组(31例)。两组均给予常规纠正心衰治疗(休息、限钠、洋地黄、利尿剂、ACEI和醛固酮拮抗剂),美托洛尔组在常规纠正心衰治疗基础上加服美托洛尔。观察两组治疗前及治疗5个月后临床症状、体征、心输出量(CO)、心脏指数(CI)、左室舒张末期内径(LVEDD)及左室射血分数(EF)等的改变情况,并采用免疫放射分析(IRMA)测定血浆BNP水平。结果治疗5个月后,两组症状、体征、CO、CI、LVEDD、EF均明显改善,血浆中BNP水平均较治疗前下降,且美托洛尔组血浆BNP水平(200.6±12.1ng/ml)明显低于对照组(120.7±14.1ng/ml,P<0.01)。结论CHF患者接受选择性β受体阻滞剂治疗后,可显著改善心脏内分泌功能,可能有助于改善心衰预后。

【Abstract】 Objective To investigate the dynamic changes in brain natriuretic peptide (BNP) and the outcome of patients with chronic congestive heart failure (CHF) after the treatment with metoprolol. Methods Sixty-five patients with CHF were admitted to the Forth Affiliated Hospital of Zhengzhou University during April 2004 to April 2007, and they fulfilled the diagnostic criteria of chronic CHF issued by New York Heart Association (NYHA). Of all the patients the left ventricular end-diastolic dimension (LVEDD) ≥65mm. All the patients were randomly assigned into metoprolol group (34 cases) and control group (31 cases), and received conventional therapies [rest, reduced sodium intake, administration of digitalis, diuretic, angiotensin-converting enzyme inhibitor (ACEI) and aldosterone antagonists, etc.]. The patients in metoprolol group were given metoprolol (6.25mg as initiative dose and dose was increased according to illness). NYHA functional classitication, cardiothoracic ratio on chest X-ray film, cardiac output (CO), cardiac index (CI), left ventricular ejection fraction (EF) and LVEDD in echocardiogram were observed, and the plasma BNP level was determined with an immunoradiometric assay (IRMA). Results After 5 months of treatment, the clinical symptoms of patients were improved obviously and p1asma BNP level was significantly lowered in both groups, while p1asma BNP level was significantly lower in metoprolol group compared with control group (200.6±12.1 vs 120.7±14.1, P<0.01). Conclusion Selective beta-receptor blocker metoprolol can lower plasma BNP level and improve the endocrine function in patients with CHF, therefore a better outcome may be expected.

  • 【文献出处】 解放军医学杂志 ,Medical Journal of Chinese People’s Liberation Army , 编辑部邮箱 ,2008年05期
  • 【分类号】R541.6
  • 【被引频次】6
  • 【下载频次】105
节点文献中: 

本文链接的文献网络图示:

本文的引文网络